Rain Oncology's Phase 3 MANTRA Trial Of Milademetan In Dedifferentiated Liposarcoma, Did Not Meet Its Primary Endpoint Of Progression-Free Survival, Compared To The Standard Of Care, Trabectedin
Portfolio Pulse from Benzinga Newsdesk
Rain Oncology's Phase 3 MANTRA trial of Milademetan in dedifferentiated liposarcoma did not meet its primary endpoint of progression-free survival, compared to the standard of care, Trabectedin.
May 22, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Rain Oncology's stock may be negatively impacted as the Phase 3 MANTRA trial of Milademetan failed to meet its primary endpoint.
The failure of the Phase 3 MANTRA trial to meet its primary endpoint indicates that Milademetan may not be as effective as initially hoped. This could lead to a decrease in investor confidence and a potential drop in Rain Oncology's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100